Wei et al.Protection against mammary tumor growth by vaccination with full-length, modoified human Erb—2 DNA. International Journal of Cancer, vol. 81, pp. 748-754, 1999.* |
Geysen et al. Cognitive features of continuous antigenic determinants. J. of Molecular Recognition, vol. 1, pp. 32-40, 1988.* |
Russell et al. Structural features can be unconserved in proteins with similar folds. Journal of Molecular Biology, vol. 244, pp. 332-350, 1994.* |
Adams et al., Genbank Accession No. Q60347, 1993. |
Adams et al., Genbank Accession No. Q61250, 1993. |
Anderson et al., “Sequence and organization of the human mitochondrial genome,” Nature 290:457-465, 1981. |
Bauer et al., “Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR),” Nucleic Acids Research 21(18):4272-4280, 1993. |
Bernard et al., “Cloning and Sequencing of Pro-α1(XI) Collagen cDNA Demonstrates That Type XI Belongs to the Fibrillar Class of Collagens and Reveals That the Expression of the Gene Is Not Restricted to Cartilagenous Tissue,” J. Biol. Chem. 263(32):17159-17166, 1988. |
Bratthauer et al., “Expression of LINE-1 Retrotransposons in Human Breast Cancer,” Cancer 73:2333-2336, 1994. |
Byrne et al., “A Screening Method to Identify Genes Commonly Overexpressed in Carcinomas and the Identification of a Novel Complementary DNA Sequence,” Cancer Research 55:2869-2903, 1995. |
Chai et al., Genbank Accession No. U03644, 1994. |
Charnock-Jones et al., “Extension of incomplete cDNAs (ESTs) by biotin/streptavidin-mediated walking using polymerase chain reaction,” J. Biotechno. 35:205-215, Jun. 1994. |
Chen and Sager, “Differential Expression of Human Tissue Factor in Normal Mammary Epithelial Cells and in Carcinomas,” Molecular Medicine 1(2):153-160, 1995. |
Cordonnier et al., “Isolation of Novel Human Endogenous Retrovirus-Like Elements with Foamy Virus-Related pol Sequence,” Journal of Virology 69(9):5890-5897, 1995. |
Databank Genebank Accession No. Z34289, 1995. |
Ezzell, “Cancer “Vaccines”: An Idea Whose Time Has Come?,” The Journal of NIH Research 7:46-49, 1995. |
Frank et al., Genbank Accession No. Q70049, 1994. |
Gura, “Systems for Identifying New Drugs Are Often Faulty,” Science 278:1041-1042, 1997. |
Haltmeier et al., “Identification of S71-Related Human Endogenous Retroviral Sequences with Full-Length pol Genes,” Virology 209:550-560, 1995. |
Hillier et al., Genbank Accession No. H80165, 1995. |
Hillier et al., Genbank Accession No. R19532, 1995. |
Hillier et al., Genbank Accession No. R55637, 1995. |
Hillier et al., Genbank Accession No. R60426, 1995. |
Hillier et al., Genbank Accession No. T83348, 1995. |
Hillier et al., Genbank Accession No. R35308, 1995. |
Keydar et al., “Properties of retrovirus-like particles produced by a human breast carcinoma cell line: Immunological relationship with mouse mammary tumor virus proteins,” Proc. Natl. Acad. Sci. USA 81:4188-92, 1984. |
Leib-Mösch and Seifarth, “Evolution and Biological Significance of Human Retroelements,” Virus Genes 11(2/3):133-145, 1996. |
Leib-Mösch et al., “Endogenous Retroviral Elements in Human DNA,” Cancer Research 50:5636s-5642s, 1994. |
Leib-Mösch et al., “Genomic Distribution and Transcription of Solitary HERV-K LTRs,” Genomics 18:261-269, 1993. |
Liang et al., “Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction,” Science 257:967-971, 1992. |
Matsubara et al., Genbank Accession No. T24124, 1995. |
Wang et al., “Detection of Mammary Tumor Virus ENV Gene-like Sequences in Human Breast Cancer,” Cancer Research 55:5173-5179, 1995. |
Watson and Fleming, “Isolation of Differentially Expressed Sequence Tags from Human Breast Cancer,” Cancer Research 54(17):4598-4602, 1994. |
Werner et al., “S71 Is a Phylogenetically Distinct Human Endogenous Retroviral Element with Structural and Sequence Homology to Simian Sarcoma Virus (SSV),” Virology 174:225-238, 1990. |
Yoshioka et al., “Pro-α1(XI) Collagen. Structure Of The Amino-Terminal Propeptide And Expression Of The Gene In Tumor Cell Lines,” J. Biol. Chem. 265(11):6423-6426, 1990. |
Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, Presentation of the Intellectual Property Committee of the Biotechnology Industry Organization at the Oct. 17, 1994, Hearing of the U.S. Patent and Trademark Office, San Diego, CA, published by the Biotechnology Industry Organization, Washington, D.C., pp. 75, 100-107. 1994. |
Ahmed et al., “Characterization of a retrovirus isolated form normal mink cells co-cultivated with a dog mammary tumour,” J. Gen. Virol. 42:179-184, 1979. |
Bakker et al., “Generation of antimelanoma cytotoxic T lymphocytes for healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vivo,” Cancer Research 55:5330-5334, Nov. 15, 1995. |
Cease et al., “T cell clones specific for an amphipathic α-helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides,” Journal of Experimental Medicine 164:1779-1784, Nov. 1986. |
Derks et al., “Synthesis of a viral protein with molecular weight of 30,000 (p30) by leukemic cells and antibodies cross-reacting with simian sarcoma virus p30 in serum of a chronic myeloid leukemia patient,” Cancer Research 42:681-686, Feb. 1982. |
Hehlmann et al., “Detection and biochemical characterization of antigens in human leukemic sera that cross-react with primate C-type viral proteins (M 30,000)1,” Cancer Research 43:392-399, Jan. 1983. |
Herbrink et al., “Detection of antibodies cross-reactive with type C RNA tumor viral p30 protein in human sera and exudate fluids,” Cancer Research 40:166-173, Jan. 1980. |
Hopp, T., “Computer prediction of protein surface features and antigenic determinants,” Molecular Basis of Cancer Part B: Macromolecular Recognition, Chemotherapy, and Immunology:367-377, 1985. |
Jerabek et al., “Detection and immunochemical characterization of a primate type C retrovirus-related p30 protein in normal human placentas,” Proc. Natl. Acad. Sci. USA 81:6501-6505, Oct. 1984. |
Kast et al., “Role of HLA-A motifs in identification of potential CTL epitopes in human papillmavirus type 16 E6 and E7 proteins,” J. Immunol. 152:3904-3912, 1994. |
Kawakami et al., “Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression,” J. Immunol. 154:3961-3968, 1995. |
Maeda et al., “Serum antibody reacting with placental syncytiotrophoblast in sera of patients with autoimmune diseases—a possible relation to type C RNA retroviruses,” Clin. Exp. Immunol. 60:645-653, 1985. |
Margalit et al., “Prediction of immunodominant helper T cell antigenic sites from the primary sequence,” The Journal of Immunology 138(7):2213-2229, Apr. 1, 1987. |
McCombs, R., “Role of oncornaviruses in carcinoma of the prostate,” Cancer Treatment Reports 61(2):131-132, Mar./Apr. 1977. |
Porter-Jordan and Lippman et al., “Overview of the biologic markers of breast cancer,” Breast Cancer 8(1):73-100, Feb. 1994. |
Rammensee et al., “MHC ligands and peptide motifs: first listing,” Immunogenetics 41:178-228, 1995. |
Rothbard and Taylor, “A sequence pattern common to T cell epitopes,” The EMBO Journal 7(1):93-100, Jan. 1988. |
Sette et al., “The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes,” J. Immunol. 153:5586-5592, 1994. |
Smith et al., “Expression of antigenic crossreactivity to RD114 p30 protein in a human fibrosarcoma cell line,” Proc. Natl. Acad. Sci. USA 74(2):744-748, Feb. 1977. |
Spouge et al., “Strong conformational propensities enhance T cell antigenicity,” The Journal of Immunology 138(1):204-212, Jan. 1987. |
Tsai et al., “In vitro immunization and expansion of antigen-specific cytotoxic T-lymphocytes for adoptive immunotherapy using peptide pulsed dendritic cells,” Critical Reviews in Immunology 18:65-75, 1998. |
Vaczi and Toth, “Studies on antigens of C-type primate viruses and antibodies to them at patients wit myeloid leukemia and potentially preleukemic hematological disorders,” Arch. Geschwulstforsch 50(8):769-777, 1980. |
Visseren et al., “CTL specific for the tyrosinase autoantigen can be induced form healthy donor blood to lyse melanoma cells,” J. Immunol 154:3991-3998, 1995. |
Vitiello et al., “Analysis of the HLA-restricted influenza specific cytotoxic T lymphcyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatability complex,” J. Exp. Med. 173:1007-1015, Apr. 1991. |
Wiley and Cunningham, “A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands,” Cell 25:433-440, Aug. 1981. |
GenBank Accession No. Z34289, “H. sapiens mRNA for nucleolar phosphoprotein p130,” Jun. 1, 1995. |
Ahn and Kunkel, “The structural and functional diversity of dystrophin,” Nature Genetics 3:283-291, Apr. 1993. |
Attwood, T.K., “The Babel of Bioinformatices,” Science 290:471-473, Oct. 20, 2000. |
Boon, T., “Toward a Genetic Analysis of Tumor Rejection Antigens,” Adv. Cancer Res. 58:177-210, 1982. |
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” Journal of Cell Biology 111:2129-2138, Nov. 1990. |
Cawthon et al., “cDNA Sequence and Genomic Structure of EV12B, a Gene Lying with an Intron of the Neurofibromatosis Type 1 gene,” Genomics 9: 446-460, 1991. |
Curti, B.D., “Physical barriers to drug delivery in tumors,” Critical Reviews in Oncology/Hematology 14:29-39, 1993. |
Dermer, G.B., “Another Anniversary for the War on Cancer,” Bio/Technology 12:320, Mar. 1994. |
Drexler, H. “Recent Results on the Biology of Hodgkin and Reed-Sternberg cells. II. Continuous Cell Lines,” Leukemia and Lymphoma 9: 1-25, 1993. |
Embleton, M.J., “Monoclonal Antibodies to Osteogenic Sarcoma Antigens,” in Monoclonal Antibodies and Cancer, Immunology Series 23, Wright, Jr. G.L. (ed.), Marcel Dekker, New York, NY, 1984, pp. 181-207. |
Freshney, R.I., Culture of Animal Cells: A Manual of Basic Technique, Alan R. Liss, Inc., New York, 1983, pp. 3-4. |
GenBank Accession No. AA533501, Aug. 1, 1997. |
GenBank Accession No. AC018804, Feb. 11, 2003. |
GenBank Accession No. AI804733, Jul. 6, 1999. |
GenBank Accession No. AQ063365, Jul. 30, 1998. |
GenBank Accession No. AQ124119, Aug. 31, 1998. |
Geneseq (Derwent) Accession No. AAV68996, Jan. 22, 1999. |
Genseq (Derwent) Accession No. AAL10921, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL11383, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL11455, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL13620, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL18685, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL20282, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL20354, Dec. 7, 2001. |
Genseq (Derwent) Accession No. AAL22489. Dec. 7, 2001. |
Gerhold and Caskey, “It's the genes! EST access to human genome content,” BioEssays 18(12): 973-981, 1996. |
Gillies and Wesolowski et al., “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities,” Hum. Antibod. Hybridomas 1(1): 47-54, 1990. |
Harris et al., “Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect,” Journal of the American Society of Nephrology 6(4): 1125-1133, Oct. 1995. |
Hartwell et al., “Integrating Genetic Approaches into the Discovery of Anticancer Drugs,” Science 278: 1064-1068, Nov. 7, 1997. |
Hsu, T.C., “Karyology of Cells in Culture,” in Tissue Culture: Methods and Applications, Kurse, Jr et al. (eds.), Academic Press, New York, 1973, pp. 764-767. |
Jain, R. K., “Barriers to Drug Delivery in Solid Tumors,” Scientific American 271(1): 58-65, Jul. 1994. |
Johnstone and Thorpe (eds.), Immunochemistry in Practice, Second Edition, Blackwell Scientific Publications, Oxford England, 1987, pp. 49-50. |
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology 8: 1247-1252, Mar. 1988. |
Tao and Morrison, “Studies of Aglycosylated Chimeric Mouse-Human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,” Journal of Immunity 143(8): 2595-2601, Oct. 15, 1989. |
Venter et al., “Genome sequence analysis: scientific objectives and practical strategies,” Trends in Biotechnology 10:8-11, Jan./Feb. 1992. |
Walter, G., “Production of use of antibodies against synthetic peptides,” Journal of Immunological Methods 88: 149-161, 1986. |
Wells and Peitsch, “The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases,” Journal of Leukocyte Biology 61:545-550, May 1997. |